BIO-TECHNE Corp vs Teck Resources — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Teck Resources trades at $65.7 (market cap $32.19B). The key difference: Teck Resources is far larger — about 2.8× BIO-TECHNE Corp's market cap, and Teck Resources pays the higher dividend (0.54%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Teck Resources for 13 Days on average.
| TECH | TECK | |
|---|---|---|
Market Cap | $11.37B | $32.19B |
Volume | 3,153,511 | 1,489,977 |
Sector | Health | Basic Materials |
52-Week High | $72.61 | $71.97 |
52-Week Low | $43.31 | $38.23 |
Typical Hold Time | 63 Days | 13 Days |
Enterprise Value | $11.40B | $34.82B |
Dividend Yield | 0.44% | 0.54% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Teck Resources is a mining company focused on producing metals and minerals, including copper and zinc. Its operations supply materials used in infrastructure, manufacturing, and energy-related industries.
Read more on TECK →